Beigene has submitted the IND application for its anti-EGFR×c-MET×c-MET tri-specific antibody BG-T187 in China. This marks the company's first in-house tri-specific antibody entering the clinical stage. In NSCLC, BeiGene has strategically targeted numerous molecular pathways, including PD-1, TIGIT, TIM3, LAG3, OX40, PanKRASi, HPK1, PRMT5i, B7H3 ADC, CEA ADC, and EGFR degrader. BG-T187 EGFR is a critical biomarker for the diagnosis and treatment of non-small cell lung cancer (NSCLC). Beigene had not previously targeted this pathway, but they have now discovered therapeutic approaches beyond single inhibitors, such as TsAb and degraders. Prevalence of EGFRm in NSCLC BG-T187 is an anti-EGFR×c-MET×c-MET tri-specific antibody that is registered as a monotherapy or in combo with the other therapeutic agents (not disclosed) in the phase 1 trial ( NCT06598800 ). In 2023, Beigene submitted a patent (WO2024153168) covering anti-cMET antibodies, including multispecific antibodies such as the
CBX - China Biotech XYZ
China Biotech XYZ Shares Updates Related to New Drug Development in China